Economic Evaluations of Treatments for Systemic Fungal Infections
- 1 January 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 22 (7), 421-433
- https://doi.org/10.2165/00019053-200422070-00002
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Cost Effectiveness of Amphotericin B plus G-CSF Compared with Amphotericin B MonotherapyPharmacoEconomics, 1999
- Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic PatientsPharmacoEconomics, 1998
- Plasma Itraconazole Concentrations in Patients With NeutropeniaTherapeutic Drug Monitoring, 1997
- The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS PatientsMedical Decision Making, 1997
- Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysisJournal of Hospital Infection, 1996
- Results of the Economic Evaluation of the FIRST Study:A Multinational Prospective Economic EvaluationInternational Journal of Technology Assessment in Health Care, 1996
- Risk Factors for Fungal Infection in Patients with Malignant Hematologic Disorders: Implications for Empirical Therapy and ProphylaxisClinical Infectious Diseases, 1994
- Cost-Effectiveness Analysis of Treatment with Liposomal Amphotericin B versus Conventional Amphotericin B in Organ or Bone Marrow Transplant Recipients with Systemic MycosesPharmacoEconomics, 1992
- Economic Analysis in Randomized Control TrialsMedical Care, 1992
- Cost implications of alternative treatments for aids patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin b-based therapiesJournal of Infection, 1991